ECSP045297A - Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn? - Google Patents

Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?

Info

Publication number
ECSP045297A
ECSP045297A EC2004005297A ECSP045297A ECSP045297A EC SP045297 A ECSP045297 A EC SP045297A EC 2004005297 A EC2004005297 A EC 2004005297A EC SP045297 A ECSP045297 A EC SP045297A EC SP045297 A ECSP045297 A EC SP045297A
Authority
EC
Ecuador
Prior art keywords
inhibitors
microgly
interleucine
ifn
interrupt
Prior art date
Application number
EC2004005297A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045297A publication Critical patent/ECSP045297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere al uso de inhibidores de la microglía para preparar fármacos que inhiben las reacciones inmunes asociadas con monocitos, macrófagos y células-T y a su uso para el tratamiento de enfermedades inmunológicas asociadas con células-T y reacciones inflamatorias no asociadas con células-T.
EC2004005297A 2002-02-15 2004-09-14 Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn? ECSP045297A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (de) 2002-02-15 2002-02-15 Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen

Publications (1)

Publication Number Publication Date
ECSP045297A true ECSP045297A (es) 2004-10-26

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005297A ECSP045297A (es) 2002-02-15 2004-09-14 Inhibidores de la microglía para interrumpir reacciones inmunes asociadas con interleucina 12 y ifn?

Country Status (21)

Country Link
EP (1) EP1474138A1 (es)
JP (1) JP2005522447A (es)
KR (1) KR20040084909A (es)
CN (1) CN1756546A (es)
AR (1) AR039556A1 (es)
AU (1) AU2003245523A1 (es)
BR (1) BR0307706A (es)
CA (1) CA2475770A1 (es)
DE (1) DE10207843A1 (es)
EC (1) ECSP045297A (es)
MX (1) MXPA04007943A (es)
NO (1) NO20043840L (es)
PE (1) PE20030906A1 (es)
PL (1) PL371327A1 (es)
RS (1) RS71304A (es)
RU (1) RU2004127677A (es)
TW (1) TW200306823A (es)
UA (1) UA81111C2 (es)
UY (1) UY27662A1 (es)
WO (1) WO2003068225A1 (es)
ZA (1) ZA200407382B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US7820637B2 (en) * 2005-03-17 2010-10-26 Proyecto De Biomedicina Cima, S.L. Use of 5′-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
EP3390367B1 (en) * 2015-12-15 2020-09-09 The Board of Trustees of the Leland Stanford Junior University Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
TW201734003A (zh) 2016-01-05 2017-10-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之吡啶及嘧啶化合物
AR108875A1 (es) 2016-06-24 2018-10-03 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AU2018350980C1 (en) 2017-10-18 2024-12-12 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
CN112341451B (zh) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341450B (zh) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
CA3165339A1 (en) * 2019-12-19 2021-06-24 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Cd206 modulators their use and methods for preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
NZ519326A (en) * 2000-01-14 2005-02-25 Schering Ag 1,2-diarylbenzimidazoles for treating diseases that are associated with a microglia activation
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
TW200306823A (en) 2003-12-01
JP2005522447A (ja) 2005-07-28
BR0307706A (pt) 2005-01-11
PE20030906A1 (es) 2004-01-17
MXPA04007943A (es) 2004-11-26
ZA200407382B (en) 2005-09-14
UA81111C2 (en) 2007-12-10
WO2003068225A1 (de) 2003-08-21
KR20040084909A (ko) 2004-10-06
AU2003245523A1 (en) 2003-09-04
CN1756546A (zh) 2006-04-05
RS71304A (sr) 2006-10-27
NO20043840L (no) 2004-11-12
AR039556A1 (es) 2005-02-23
CA2475770A1 (en) 2003-08-21
DE10207843A1 (de) 2003-09-04
UY27662A1 (es) 2003-09-30
PL371327A1 (en) 2005-06-13
RU2004127677A (ru) 2005-06-10
EP1474138A1 (de) 2004-11-10

Similar Documents

Publication Publication Date Title
UY27662A1 (es) Inhibidores de la mocroglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny.
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
MXPA03008955A (es) Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
ES2246567T3 (es) Composiciones para receptores inhibidores de celulas t y usos de las mismas.
CR7875A (es) Variantes de inmunoglobina y usos de esto
ES2148525T3 (es) Inmunomoduladores.
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
UY27720A1 (es) Aroilpiridinonas monocíclicas,
MX9400166A (es) Microesferas de proteina vegetal, hidrolizada, modificada y metodos para su preparacion y su uso.
ES2132068T3 (es) Factor inhibidor de la sintesis de la citoquina y metodos para usarlo.
RS20120139A3 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
ATE213952T1 (de) Freisetzung und mobilisierung hämatopoietischer zellen
CL2003002678A1 (es) Compuestos derivados de piperidina, moduladores de la actividad del receptor ccr5; procedimiento de preparacion; composicion farmaceutica, y su uso en el tratamiento de enfermedades inmunologicas, inflamatorias, asma, artritis reumatoidea y ateroescl
DE60041655D1 (de) Auslösender rezeptor der an der natürlichen cytotoxizität der menschlichen natürlichen killerzellen (natural killer cells) beteiligt ist und antikörper die diesen rezeptor identifizieren
EP1578373A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
PT1017667E (pt) 2-amino-6-metil-7-acetil-tetralina e composicoes farmaceuticas para a prevencao e para o tratamento terapeutico de patologias inflamatorias e/ou de natureza autoimunitaria
UY27312A1 (es) Nuevos heterociclos 3
CR7441A (es) Inhibidores de la microglia para interrumpir reacciones inmunes asociadas con interleucina 12 y ifny
ATE57526T1 (de) P-acylaminobenzamide.
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
ECSP045296A (es) Derivados de benzimidazol 1-fenil-2-heteroaril-sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunológicas